SiBone (NASDAQ:SIBN) SVP Michael Pisetsky Sells 20,756 Shares

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 20,756 shares of SiBone stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $15.35, for a total value of $318,604.60. Following the completion of the sale, the senior vice president owned 285,974 shares of the company’s stock, valued at approximately $4,389,700.90. The trade was a 6.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

SiBone Trading Up 3.2%

Shares of SiBone stock traded up $0.49 on Wednesday, reaching $15.74. 569,275 shares of the company’s stock were exchanged, compared to its average volume of 551,190. The company has a market capitalization of $682.97 million, a P/E ratio of -30.86 and a beta of 0.69. SiBone has a 52 week low of $12.49 and a 52 week high of $21.89. The firm’s 50-day moving average is $18.03 and its two-hundred day moving average is $16.86. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.62 and a current ratio of 7.97.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of SIBN. Royal Bank of Canada lifted its stake in SiBone by 98.5% in the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock valued at $29,000 after purchasing an additional 736 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of SiBone by 0.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 225,001 shares of the company’s stock valued at $4,437,000 after buying an additional 997 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of SiBone by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after buying an additional 1,053 shares during the last quarter. Larson Financial Group LLC grew its stake in shares of SiBone by 42.3% during the 4th quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock worth $70,000 after acquiring an additional 1,061 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of SiBone by 4.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,159 shares of the company’s stock worth $733,000 after acquiring an additional 1,459 shares during the period. 98.11% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on SIBN shares. Needham & Company LLC boosted their target price on shares of SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Morgan Stanley upped their target price on shares of SiBone from $20.00 to $23.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Truist Financial raised their price target on shares of SiBone from $21.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Canaccord Genuity Group boosted their price target on shares of SiBone from $26.00 to $27.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Finally, TD Cowen upgraded shares of SiBone to a “strong-buy” rating in a research note on Tuesday, January 27th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $24.33.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.